Actively Recruiting
Studying TRAIL-R2 and HER2 Bi-Specific CAR T Cell Therapy for Metastatic Breast Cancer Treatment
Led by Baylor College of Medicine · Updated on 2026-09-24
27
Participants Needed
1
Research Sites
782 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new gene therapy using special immune cells called HTR2 T cells to treat metastatic breast cancer that expresses the HER2 protein and has progressed after at least one prior treatment. This phase 1 study aims to find the highest safe dose of these modified T cells, understand how long they last in the body, learn about possible side effects, and evaluate their ability to attack and kill cancer cells. The therapy combines T cells engineered to target HER2 with an antibody to block immune-suppressive cells and a supportive protein called interleukin 15 to improve T cell function. The treatment involves collecting a patients own T cells, modifying them in the lab with genes for HER2 targeting, the TR2 antibody, and interleukin 15 using a retrovirus, then freezing the cells. When ready, the frozen HTR2 T cells are thawed and infused back into the patient over 5 to 10 minutes. Patients receive one infusion per treatment cycle, with possible repeat infusions if tolerated and effective. Two groups will be studied one receiving HTR2 T cells without lymphodepletion and one with lymphodepletion, each at two different dose levels. If severe side effects occur, a special gene inserted in the T cells allows doctors to eliminate them using an experimental drug. Before treatment, patients undergo medical exams, blood tests, scans, heart ultrasound, and tumor biopsies to confirm HER2 status. After infusion, they are closely monitored weekly for 4 weeks, then every 3 months for the first year, and every 6 months up to 5 years, including physical exams, blood tests, and tumor scans. Blood samples will be collected frequently to study the persistence of T cells, and additional tumor biopsies may be taken as needed. Participants may be followed for up to 15 years to assess long-term effects and treatment outcomes.
CONDITIONS
Brief Title
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Research Team
N
Natalie Chen, MD
W
Wendy Callejas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here